Affiliation:
1. Department of Medical Oncology, Ramon y Cajal University Hospital, 28034 Madrid, Spain
Abstract
Metastatic colorectal cancer (mCRC) with mutated BRAF exhibits distinct biological and molecular features that set it apart from other subtypes of CRC. Current standard treatment for these tumors involves a combination of chemotherapy (CT) and VEGF inhibitors. Recently, targeted therapy against BRAF and immunotherapy (IT) for cases with microsatellite instability (MSI) have been integrated into clinical practice. While targeted therapy has shown promising results, resistance to treatment eventually develops in a significant portion of responsive patients. This article aims to review the available literature on mechanisms of resistance to BRAF inhibitors (BRAFis) and potential therapeutic strategies to overcome them.
Reference74 articles.
1. BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer;Ros;Ther. Adv. Med. Oncol.,2021
2. Molina-Cerrillo, J., San Román, M., Pozas, J., Alonso-Gordoa, T., Pozas, M., Conde, E., Rosas, M., Grande, E., García-Bermejo, M.L., and Carrato, A. (2020). BRAF Mutated Colorectal Cancer: New Treatment Approaches. Cancers, 12.
3. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors;Rawla;Prz. Gastroenterol.,2019
4. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF -Mutant Colorectal Cancer;Oddo;Cancer Res.,2016
5. BRAF -Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape;Ciombor;J. Clin. Oncol.,2022
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献